IFPMA says member companies have over 100 R&D Projects for diseases of the developing world; names new president and VPs

11 November 2010

The increasing efforts of International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) member companies, working with partners or alone, to develop medicines and vaccines for the 10 diseases of the developing world (DDW) prioritized by the TDR tropical disease research and training organization are highlighted in a new report from the trade group, titled Status Report on Pharmaceutical Industry R&D for Diseases of the Developing World.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical